期刊
MEDICINAL RESEARCH REVIEWS
卷 41, 期 1, 页码 507-524出版社
WILEY
DOI: 10.1002/med.21738
关键词
hepatocellular carcinoma; hepatocyte growth factor; c-mesenchymal-epithelial transition factor
资金
- Research Grants Council of the Hong Kong SAR [CUHK14117015]
Hepatocellular carcinoma is a major cause of cancer mortality worldwide, with current treatments showing unsatisfactory outcomes. The HGF/c-Met axis is considered crucial in regulating liver diseases and promoting HCC, and inhibiting this pathway may lead to the development of new and effective treatments for HCC.
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide. The outcome of current standard treatments, as well as targeted therapies in advanced stages, are still unsatisfactory. Attention has been drawn to novel strategies for better treatment efficacy. Hepatocyte growth factor/c-mesenchymal-epithelial transition factor (HGF/c-Met) axis has been known as an essential element in the regulation of liver diseases and as an oncogenic factor in HCC. In this review, we collected the evidence of HGF/c-Met as a tumor progression and prognostic marker, discussed the anti-c-Met therapy in vitro, summarized the outcome of c-Met inhibitors in clinical trials, and identified potential impetus for future anti-c-Met treatments. We also analyzed the inconsistency of HGF/c-Met from various publications and offered reasonable explanations based on the current understanding in this area. In conclusion, HGF/c-Met plays a crucial role in the progression and growth of HCC, and the strategies to inhibit this pathway may facilitate the development of new and effective treatments for HCC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据